Human Medicine - Inflammatory diseases

European Hematology Association June 2017

22/06/2017 –

MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBOCONTROLLED, PHASE 3 STUDY
The New England Journal of Medicine May 2017

18/05/2017 –

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
The Lancet – Masitinib in Mastocytosis Phase 3

06/01/2017 –

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
Brœsby 2013-J Allergy Clin Immunol

12/04/2013 – KIT D816V mutation burden dœs not correlate to clinical manifestations of indolent systemic mastocytosis
PLoSONE 2011 Moura-MASITINIB AND DEPRESSION IN MASTOCYTOSIS

21/10/2011 – Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
Am. J. Hematol 2010 Paul – MASITINIB IN MASTOCYTOSIS P2

23/11/2010 – Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study.
Allergy 2009 Humbert – MASITINIB IN ASTHMA P2

27/07/2009 – Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Arthritis Res Ther 2009 Walker-EDITORIAL

13/07/2009 – More about masitinib – Ulrich A Walker

Human Medicine – Inflammatory diseases